Grupo para la caracterización molecular de las neoplasias hematológicas
Klinikum der Universität München
Múnich, AlemaniaPublicaciones en colaboración con investigadores/as de Klinikum der Universität München (6)
2022
-
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
Blood Advances, Vol. 6, Núm. 22, pp. 5835-5843
-
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
New England Journal of Medicine, Vol. 386, Núm. 7, pp. 629-639
-
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nature Medicine, Vol. 28, Núm. 2, pp. 325-332
2018
-
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 11, pp. 1530-1542
2014
-
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database
Nature Genetics, Vol. 46, Núm. 2, pp. 107-115